Study S001402

Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00422058
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 564
Start: 2007-01-10
Primary completion: 2007-09-13
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:liraglutide; DRUG:orlistat; DRUG:placebo
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2006-004481-13

Registered primary outcomes

Mean Change From Baseline in Body Weight at Week 20 [Week 0, week 20]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013170	Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Davies MJ, Diabetes, obesity & metabolism	2018	Systematic review	PMID 28950422 DOI	registry reference RESULT:28950422
R0022210	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. O'Neil PM, Diabetes, obesity & metabolism	2017	Randomized trial	PMID 28386912 DOI	registry reference RESULT:28386912
R0025365	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Steinberg WM, Diabetes care	2017	Randomized trial	PMID 28473337 DOI	registry reference RESULT:28473337
R0026705	Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Lean ME, International journal of obesity (2005)	2014	Randomized trial	PMID 23942319 DOI	cites ClinicalTrials.gov:NCT00422058; registry reference RESULT:23942319
R0025439	Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Astrup A, International journal of obesity (2005)	2012	Randomized trial	PMID 21844879 DOI	registry reference RESULT:21844879
R0027293	Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Astrup A, Lancet (London, England)	2009	Randomized trial	PMID 19853906 DOI	cites ClinicalTrials.gov:NCT00422058; registry reference RESULT:19853906